Your AI-Trained Oncology Knowledge Connection!
Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).
Use of the NovoTTF system along with adjuvant temozolomide led to longer progression-free survival and overall survival in patients with glioblastoma.
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).
The vaccine rindopepimut appears to help PFS and OS in patients with epidermal growth factor receptor variant III mutation in glioblastoma-a patient group with traditionally poor outcomes.
Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands, discusses the BELOB trial, which examined bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma.
The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, discusses the ReACT study, which examined the rindopepimut vaccine (CDX-110) plus bevacizumab in patients with relapsed glioblastoma.
The vaccine rindopepimut plus bevacizumab induced tumor regression in a subset of patients with recurrent glioblastoma.
The combination of bevacizumab and lomustine showed superior efficacy compared with either agent alone in patients with recurrent glioblastoma, warranting further study.
Roeland GW Verhaak, PhD, Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, discusses a study that examined the comprehensive and integrative genomic characterization of diffuse lower grade gliomas.
The combination of radiation therapy with procarbazine, CCNU, and vincristine prolonged OS and PFS compared with radiation therapy alone in grade 2 glioma.
Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses how targeting MEK can be an effective treatment strategy for CNS metastasis.
Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.
How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?
Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.
Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.
Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.
Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.
Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.
Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer
Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.
Translating current and emerging knowledge of the molecular drivers of ovarian cancer is yielding promising new insights into potential clinical targets, moving treatment away from historical paradigms in favor of more personalized therapeutic approaches.
PARP inhibitors represent an important class of emerging therapies for the treatment of patients with ovarian cancer and possibly other malignancies, but many scientific questions about the underlying molecular mechanisms that these agents target must be answered before they can be fully employed in clinical practice.
In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.
When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what's ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.
The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms
As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens
The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.
